Videos

Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.

The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.

Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.

An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.

Insight from cardiologist Anees A. Daud, MD, following his viewing of AbbVie’s educational video on cardiovascular risk and androgen deprivation therapy.

Insight from Urologist David Morris, MD, FACS, as he reacts to the educational video from AbbVie on cardiovascular risk and androgen deprivation therapy.

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

David Morris, MD, FACS, shares advice on followup with patients on androgen deprivation therapy for prostate cancer.

Stacey A. Cohen, MD, and Aparna Parikh, MD, MS, review the design and outcomes of key clinical trials exploring the use of ctDNA assays in colorectal cancer.

The panel reviews the different settings in colorectal cancer where ctDNA is being investigated as a tool for treatment and monitoring.

Expert and patient perspectives on the communication that occurs leading up to and following a diagnosis of renal cell carcinoma.

Healthcare professionals contextualize Terri Blalock’s experience by highlighting the typical presentation of RCC and elucidating workup procedures used to confirm a diagnosis.

Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.

Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.

Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).

The panel discusses which patients they would consider switching between immunotherapy combination treatments.

Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider use of CAR T-cell therapy or bispecifics in this setting.

The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.

A look at the quality of life of patients with multiple myeloma who received CAR T-cell therapy.

An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.

Paolo Tarantino, MD, explains his approach to treating patients with triple-negative breast cancer who progress early after completing adjuvant therapy.

An overview of antibody-drug conjugates in the recurrent triple-negative breast cancer treatment landscape, and the ASCENT and DESTINY-Breast04 trials.

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .

An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Joelle Hamilton, MD, reflects on strategies used in oncology practice to mitigate cardiovascular risk in patients with prostate cancer.